0858 (0858) Fair Value & Analysis

Healthcare · Market cap HK$186M

0 0858 0858 · HK

PriceHK$0.0640

Fair ValueHK$0.0626

Upside-2.2%

Quality44/100

Evidence: Medium Range HK$0.0506 – HK$0.0734

Fair value as of: Jul 2, 2026

From 10 valuation models · updated today

Share price −22.0% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.0510 – HK$0.1380 · fair‑value band HK$0.0506 – HK$0.0734 · the HK$0.0640 price screens above the HK$0.0626 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0858 (0858) currently trades at HK$0.0640, while our model-based Fair Value estimate is HK$0.0626 — implying the stock looks roughly 2.2% overvalued today. We read business quality at 44/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Trailing-twelve-month revenue stands at HK$52.6M. Revenue declined 9.0% year over year. It earns a return on equity of -32.0%. Net debt stands at HK$63.2M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$52.6M

Revenue growth (YoY) -9.0%

Return on equity -32.0%

Free cash flow −HK$7.4M FY2025

Operating margin -14.8%

EPS (TTM) HK$-0.1900

More key figures

EPS growth (YoY) +12.5%

Net debt HK$63.2M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

0858 reported revenue of HK$55.4M in FY2025 versus HK$78.8M in FY2021, a compound −8.4%/yr. Reported net income was HK$223M in FY2025.

Revenue −8.4%/yr

FY21 HK$78.8M

FY22 HK$73.9M

FY23 HK$72.6M

FY24 HK$59.1M

FY25 HK$55.4M

Net income

FY21 −HK$121M

FY22 HK$131M

FY23 HK$129M

FY24 −HK$163M

FY25 HK$223M

Is 0858 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.01	¥26.59	-43%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$26.19	R$26.01	-1%
Hansoh Pharmaceutical Group 3692	HK$29.58	HK$18.75	-37%
Divi's Laboratories Limited DIVISLAB	₹6,788	₹2,035	-70%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 0858 (0858) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.0626 versus a price of HK$0.0640 — about −2% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 0858?

Our model-based fair value for 0858 is HK$0.0626 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.0640.

What is the quality score of 0858?

0858 has a Quality Score of 44/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 0858 (0858)?

0858 reported trailing-twelve-month revenue of about HK$52.6M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 0858?

The net profit margin of 0858 is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.